IL210717A - Preparations for use in inhibiting dengue virus infection and increasing antibody-mediated dengue infection - Google Patents

Preparations for use in inhibiting dengue virus infection and increasing antibody-mediated dengue infection

Info

Publication number
IL210717A
IL210717A IL210717A IL21071711A IL210717A IL 210717 A IL210717 A IL 210717A IL 210717 A IL210717 A IL 210717A IL 21071711 A IL21071711 A IL 21071711A IL 210717 A IL210717 A IL 210717A
Authority
IL
Israel
Prior art keywords
infections
antibody
composition
dengue
inhibiting
Prior art date
Application number
IL210717A
Other languages
English (en)
Hebrew (he)
Other versions
IL210717A0 (en
Original Assignee
Trinity Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trinity Therapeutics Inc filed Critical Trinity Therapeutics Inc
Publication of IL210717A0 publication Critical patent/IL210717A0/en
Publication of IL210717A publication Critical patent/IL210717A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10Peptides having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10RNA viruses
    • C07K16/116Togaviridae (F); Matonaviridae (F); Flaviviridae (F)
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL210717A 2008-07-18 2011-01-18 Preparations for use in inhibiting dengue virus infection and increasing antibody-mediated dengue infection IL210717A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8194308P 2008-07-18 2008-07-18
PCT/US2009/050966 WO2010009380A2 (en) 2008-07-18 2009-07-17 Methods for treating immune-mediated dengue fever infections and antibody-dependent enhancement of dengue fever infections, including dengue hemorrhagic fever and dengue shock syndrome

Publications (2)

Publication Number Publication Date
IL210717A0 IL210717A0 (en) 2011-03-31
IL210717A true IL210717A (en) 2017-07-31

Family

ID=41551029

Family Applications (1)

Application Number Title Priority Date Filing Date
IL210717A IL210717A (en) 2008-07-18 2011-01-18 Preparations for use in inhibiting dengue virus infection and increasing antibody-mediated dengue infection

Country Status (13)

Country Link
US (1) US8815813B2 (https=)
EP (1) EP2320924B1 (https=)
JP (1) JP5806112B2 (https=)
CN (1) CN102159231B (https=)
AU (2) AU2009270805B2 (https=)
BR (1) BRPI0915968B1 (https=)
CA (1) CA2731218A1 (https=)
HR (1) HRP20150620T1 (https=)
IL (1) IL210717A (https=)
MX (1) MX2011000647A (https=)
MY (1) MY160699A (https=)
SG (1) SG10201500597YA (https=)
WO (1) WO2010009380A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2559887C (en) 2004-03-10 2018-12-04 Trinity Therapeutics, Inc. Method for inhibiting immune complex formation in a subject
BRPI0915968B1 (pt) 2008-07-18 2021-11-23 Trinity Therapeutics, inc Uso de polipeptídeo purificado para tratar infecção pelo vírus da dengue
WO2016106342A2 (en) * 2014-12-22 2016-06-30 Middle Tennessee State University Methods for treating immune-mediated viral infections
US10227383B2 (en) * 2015-05-20 2019-03-12 Kagoshima University Specific modification of antibody with IgG-binding peptide
WO2017189891A1 (en) * 2016-04-27 2017-11-02 Middle Tennessee State University Methods for treating zika viral infections and associated complications
SG10202012408UA (en) 2016-06-13 2021-01-28 Univ Kagoshima SITE-SPECIFIC RADIOISOTOPE-LABELED ANTIBODY USING IgG-BINDING PEPTIDE
CN115804362A (zh) * 2023-02-08 2023-03-17 中国医学科学院医学生物学研究所 一种IFN-α/βR-/-小鼠抗体依赖性增强感染的注射液及其制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5189014A (en) * 1979-12-03 1993-02-23 Cowan Jr Fred M Method of treating cellular Fc receptor mediated hypersensitivity immune disorders
US4383317A (en) * 1980-10-30 1983-05-10 Bei Electronics, Inc. Shaft angle encoder having a circuit for synthesizing a skipped track output signal
IT1190891B (it) 1982-06-24 1988-02-24 Anic Spa Metodo per la sintesi in fase solida di polipeptidi retroinvertiti
US5693758A (en) * 1987-11-19 1997-12-02 501 Research Corporation Limited Immunoglobulin E competitor
US5932483A (en) * 1990-10-16 1999-08-03 Northwestern University Synthetic peptide and its uses
EP1400536A1 (en) * 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US6420127B1 (en) * 1994-11-18 2002-07-16 Washington University Compounds and pharmaceutical compositions for the treatment and prophylaxis of bacterial infections
WO1997033603A1 (en) * 1996-03-13 1997-09-18 Trustees Of The University Of Pennsylvania Novel peptides which inhibit complement activation
ITMI962628A1 (it) 1996-12-16 1998-06-16 Tecnogen Scpa Composizione farmaceutica
WO2000015214A1 (en) * 1998-09-11 2000-03-23 Ilexus Pty Limited Fc RECEPTOR MODULATORS AND USES THEREOF
US20030190740A1 (en) 1998-10-13 2003-10-09 The University Of Georgia Research Foundation, Inc Stabilized bioactive peptides and methods of identification, synthesis, and use
EP1121425B1 (en) * 1998-10-13 2005-06-29 The University Of Georgia Research Foundation, Inc. Stabilized bioactive peptides and methods of identification, synthesis and use
EP2180054A1 (en) 1999-12-24 2010-04-28 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
ATE368688T1 (de) 2000-11-08 2007-08-15 Fresenius Medical Care Affina Peptide, deren herstellung und verwendung zur bindung von immunglobulinen
US6916904B2 (en) * 2002-04-24 2005-07-12 Zolaris Biosciences, Llc Inhibition of immune complex formation
US7351875B2 (en) 2002-06-07 2008-04-01 Trillium Therapeutics, Inc. FcγRIIa transgenic animal model for autoimmune disease
AU2002953533A0 (en) 2002-12-24 2003-01-16 Arthron Limited Fc receptor modulating compounds and compositions
CA2559887C (en) * 2004-03-10 2018-12-04 Trinity Therapeutics, Inc. Method for inhibiting immune complex formation in a subject
KR101380200B1 (ko) 2004-08-12 2014-04-01 헬신 세라퓨틱스 (유.에스.) 인크. 성장 호르몬 분비촉진제를 이용하여 위장관계의 운동성을촉진하는 방법
EP1940436B1 (en) * 2005-09-06 2013-12-04 Trinity Therapeutics, Inc. Methods for treating immune mediated neurological diseases
WO2007068047A1 (en) 2005-12-13 2007-06-21 Trillium Therapeutics Inc Multimeric fc receptor polypeptides
US20120021988A1 (en) * 2007-08-14 2012-01-26 Bodie Neil M Methods for treating immune thrombocytopenia
BRPI0915968B1 (pt) 2008-07-18 2021-11-23 Trinity Therapeutics, inc Uso de polipeptídeo purificado para tratar infecção pelo vírus da dengue

Also Published As

Publication number Publication date
CN102159231A (zh) 2011-08-17
CA2731218A1 (en) 2010-01-21
AU2009270805A1 (en) 2010-01-21
CN102159231B (zh) 2016-06-15
JP5806112B2 (ja) 2015-11-10
WO2010009380A9 (en) 2010-04-08
BRPI0915968B1 (pt) 2021-11-23
BRPI0915968A2 (pt) 2020-08-18
US20110218157A1 (en) 2011-09-08
HRP20150620T1 (xx) 2015-09-25
EP2320924A4 (en) 2012-07-25
JP2011528665A (ja) 2011-11-24
IL210717A0 (en) 2011-03-31
US8815813B2 (en) 2014-08-26
AU2009270805B2 (en) 2016-11-03
SG10201500597YA (en) 2015-04-29
EP2320924A1 (en) 2011-05-18
EP2320924B1 (en) 2015-03-11
MX2011000647A (es) 2011-09-29
HK1158066A1 (en) 2012-07-13
WO2010009380A2 (en) 2010-01-21
MY160699A (en) 2017-03-15
AU2017200760A1 (en) 2017-03-02

Similar Documents

Publication Publication Date Title
GB2471806B (en) Compositions and methods for treating viral infections
SI2079760T1 (sl) Sestavki in metode za zdravljenje okužb
IL216605A0 (en) Treatment and prevention of dengue virus infections
IL202573A0 (en) Methods and compositions for treating allergic diseases
IL210319A0 (en) Compounds and pharmaceutical compositions for the treatment of viral infections
EP2236557A4 (en) HYDROPHILIC COMPOSITION WITH MOLD-RESISTANT EFFECT AND HYDROPHILIC ELEMENT
IL195272A0 (en) Methods and compositions for the treatment of viral infections
IL210717A (en) Preparations for use in inhibiting dengue virus infection and increasing antibody-mediated dengue infection
PL2252671T3 (pl) Podobna do azeotropu kompozycja 1,1,1-trifluoro-3-chloropropenu i dimetoksymetanu
HRP20160902T1 (hr) Pripravci i postupci uporabe forbolskih estera
PT2291654T (pt) Preparação e composição de proteínas inibidoras de interalfa do sangue
EP2331123A4 (en) COMPOSITIONS AND METHODS FOR TREATING HEPATITIS C
IL208403A0 (en) Compositions and use of epas1 inhibitors
PL2252669T3 (pl) Kompozycja typu azeotropu 1,1,1-trifluoro-3-chloropropenu (HCFO-1233zd) i octanu metylu
ZA201000992B (en) Anti-viral compounds, compositions, and methods of use
ZA201007091B (en) Vaccine compositions for the treatment of dengue fever and uses thereof
ZA201002181B (en) Glycogen phosphorylase inhibitor compound and pharmaceutical composition thereof
EP2322175A4 (en) PHARMACEUTICAL COMPOSITION FOR TREATING HYPERTENSION AND METABOLIC SYNDROME AND USE THEREOF
IL178495A0 (en) Composition comprising crustacean gastrolith components and its use
IL207827A0 (en) Apoaequorin-containing compositions and methods of using same
ZA201002182B (en) Glycogen phosphorylase inhibitor compound and pharmaceutical composition thereof
ZA201004894B (en) Nuctraceutical composition and methods of use
EP2329820A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF HYPERTENSION AND METABOLIC SYNDROME AND THEIR USE
GB0601950D0 (en) Compositions and methods of treating diabetes
ZA201004893B (en) Nuctraceutical composition and methods of use

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed